To investigate the clinical relevance of PD-L1 blockade in TB progression, we analyzed pharmacovigilance data from the FAERS database, focusing on tuberculosis-related adverse events (TB-AEs) reported from Q1–2004 to Q2 2024. Here, CD274 is linked to tuberculosis.